Condition
Pulmonary Hypertension Clinical Trials
Studies of pulmonary hypertension, matched by condition name and medical subject headings. Start with those open to enrolment.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 402Pulmonary Arterial Hypertension (PAH), Quality of Life
Development and Validation of a Chinese Quality of Life Scale for Pulmonary Arterial Hypertension
This study aims to develop and validate a culturally appropriate, reliable, and clinically applicable patient-reported outcome (PRO) instrument to assess quality of life in patients with pulmonary arterial hypertension (PAH) in…
- Conditions
- Pulmonary Arterial Hypertension (PAH), Quality of Life, Patients Reported Outcomes
- Trial name
- NCT07570615
- Testing
- Questionnaire Assessment
- Volunteers
- 300 people
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
Hypertension, Pulmonary, Lung Diseases, Interstitial
Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
The primary purpose of this study is to assess the effect of TX000045 on pulmonary vascular resistance (PVR) in participants with pulmonary hypertension secondary to interstitial lung disease (PH-ILD) and to assess the safety and…
- Trial name
- NCT07473700
- Testing
- TX000045
- Where
- 16 sites in United States, Poland and 4 more
- Volunteers
- 25 people
- Sponsor
- Tectonic Operating Company, Inc.
Pulmonary Arterial Hypertension PAH
Study of Intravenous ZMA001 in Healthy Subjects
Background: A number of diseases can cause a type of lung injury called pulmonary arterial hypertension (PAH). Most people who develop PAH do not survive more than a few years. A new study drug (ZMA001) may help.
- Trial name
- NCT05967299
- Testing
- ZMA001 (BC-NKA-20008)
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Hypertension, Interstitial Lung Disease
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 (NCT07179380).
- Trial name
- NCT07234032
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 11 sites in United States, Czechia and 6 more
- Volunteers
- 344 people
- Sponsor
- Insmed Incorporated
Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Dose Finding Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease…
- Trial name
- NCT07441278
- Testing
- NS-863 Low Dose, NS-863 High Dose
- Where
- 4 sites in United States, Japan
- Volunteers
- 177 people
- Sponsor
- NS Pharma, Inc.
Pulmonary Hypertension, Interstitial Lung Disease
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.
- Trial name
- PALM-ILD (NCT07179380)
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 186 sites in United States, Argentina and 28 more
- Volunteers
- 344 people
- Sponsor
- Insmed Incorporated
Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
Background: Injury or diseases of the heart and lung can sometimes cause scar tissue (fibrosis) to build up in those organs. Current imaging scans can see this scar tissue once it has formed, but researchers want to find a way to…
- Conditions
- Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation, Interstitial Lung Disease, Acute Lung Injury
- Trial name
- NCT07613099
- Testing
- [18F]FAPI-74, 18F-FAPI-74 PET/CT Imaging
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cystic Fibrosis, Immunologic Deficiency Syndrome
Natural History of Noncirrhotic Portal Hypertension
Background: Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs.
- Conditions
- Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis
- Trial name
- NCT02417740
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Pulmonary Disease, Pulmonary Hypertension
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
Background: High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. Some people have disease-associated PAH and some have PAH from an unknown cause.
- Trial name
- NCT01730092
- Where
- United States
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Ventilator Pressure and Optimization of Compliance and Hemodynamics
In preterm infants < 34 weeks' gestation at birth receiving respiratory support with invasive positive pressure ventilation, the positive end-expiratory pressure (PEEP) of best compliance will increase the cardiac output and…
- Conditions
- Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Extreme Prematurity, Ventilator Lung; Newborn
- Trial name
- VPOCH (NCT06512935)
- Testing
- Increase in the PEEP followed by decrease in the PEEP, Decrease in the PEEP followed by increase in the PEEP
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Alabama at Birmingham
Completed, with results posted
All 238Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2
- Trial name
- Re-PHIRE (NCT05737940)
- Testing
- AZD3427
- Where
- 60 sites in United States, Austria and 12 more
- Volunteers
- 260 people
- Sponsor
- AstraZeneca
Chronic Disease, Frail
Functional Exercise and Nutrition Education Program for Older Adults
There is strong evidence that specific types of exercise can improve health and physical function in older adults. While community exercise classes exist, many older adults with chronic conditions may need guidance from…
- Conditions
- Chronic Disease, Frail, Diabetes Mellitus, Cancer
- Trial name
- MoveStrong (NCT04037436)
- Testing
- Strength and Balance Training & Nutrition Education, Usual Care
- Where
- 5 sites in Canada
- Volunteers
- 44 people
- Sponsor
- University of Waterloo
Hypertension, Pulmonary
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.
- Trial name
- CADENCE (NCT04945460)
- Testing
- Sotatercept 0.3 mg/kg, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
- Where
- 119 sites in United States, Belgium and 10 more
- Volunteers
- 165 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Pulmonary Artery Hypertension
Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension
The primary objective of this study is to determine the impact of two interventions against insulin resistance on the composite endpoint of 10% improvement in baseline six minute walk distance or improvement in World Health…
- Trial name
- NCT03617458
- Testing
- Metformin, mHealth Intervention, Usual Care
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Arterial Hypertension
Utility of At-home Monitoring of Exercise Capacity by App-based 6-minute Walk Test
Evaluate for accuracy and reproducibility of data collected via the participant-operated Walk.Talk.Track. (WTT) app combined with Apple Watch during in-clinic, technician proctored 6MWT's.
- Trial name
- DynAMITE (NCT03893500)
- Testing
- Home-based 6 minute walk test
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Stanford University